SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Significant Growth in Short Interest

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) saw a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 8,610,000 shares, a growth of 41.6% from the October 15th total of 6,080,000 shares. Based on an average daily volume of 535,900 shares, the short-interest ratio is currently 16.1 days.

SELLAS Life Sciences Group Stock Up 3.9 %

NASDAQ:SLS traded up $0.05 during mid-day trading on Friday, reaching $1.32. 861,803 shares of the company were exchanged, compared to its average volume of 1,071,800. The stock has a market cap of $84.92 million, a PE ratio of -1.91 and a beta of 2.39. SELLAS Life Sciences Group has a 12 month low of $0.50 and a 12 month high of $1.72. The company has a fifty day moving average of $1.23 and a 200 day moving average of $1.26.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. On average, equities research analysts anticipate that SELLAS Life Sciences Group will post -0.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC bought a new position in shares of SELLAS Life Sciences Group in the 2nd quarter valued at about $39,000. Anson Funds Management LP bought a new stake in shares of SELLAS Life Sciences Group during the first quarter worth approximately $4,881,000. Geode Capital Management LLC boosted its stake in SELLAS Life Sciences Group by 17.1% in the third quarter. Geode Capital Management LLC now owns 605,191 shares of the company’s stock valued at $757,000 after acquiring an additional 88,183 shares during the last quarter. State Street Corp grew its holdings in SELLAS Life Sciences Group by 30.2% during the 3rd quarter. State Street Corp now owns 174,529 shares of the company’s stock worth $218,000 after acquiring an additional 40,500 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of SELLAS Life Sciences Group during the 3rd quarter valued at $78,000. 17.38% of the stock is currently owned by institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.